Zoetis Inc.

The filings show a company whose reported revenue and earnings grew modestly in 2025 while its balance sheet became more leveraged. Total liabilities rose to $12.14 billion from $9.47 billion, and liabilities equaled about 78.5% of total assets at year-end 2025 compared with about 66.5% a year earlier. Operating cash flow was $2.9 billion in 2025 versus $2.95 billion in 2024, a slight decline, even as net income rose to $2.67 billion. The ratio of operating cash flow to net income is 1.09, meaning cash generation roughly tracked reported earnings. The forensic scores give a mixed but mostly reassuring picture. The Beneish M-Score for 2025 is -2.448, which is below the -1.78 threshold and is labeled not in the elevated zone; this is a screening result that did not flag elevated manipulation risk, not proof that the financials are accurate. The Altman Z-Score is 4.49, in the safe zone above 2.99, though it is a broad distress screen rather than a measure of this company's specific debt risk. The Piotroski F-Score is 6 of 8 computable signals, a checklist of profitability, leverage, and efficiency tests; because only the computable signals are counted, it is not directly comparable to a full nine-test scale. The Fog Index is not on file, so no readability assessment is offered here. The filing risk discussion ties the business to several items readers may want to look at: tariffs and trade measures affecting China, Canada, and the European Union; foreign exchange exposure, with about 47% of Q1 2026 revenue denominated in foreign currencies; generic competition as patents on certain key products expire; and disease outbreaks that could force production halts at main sites. The largest customer, a U.S. veterinary distributor, accounted for about 16% of 2025 revenue, a concentration worth tracking. Readers may also want to look at the Atlanta, Georgia manufacturing site purchased in 2023 and the ERP-driven fiscal alignment, since changes in timing can distort quarter-to-quarter comparisons.

Catalyst.Full-year 2025 revenue reached $9.47 billion, up 2.3% from $9.26 billion in 2024, and net income rose to $2.67 billion from $2.49 billion. In the first quarter of 2026, revenue was $2,262 million versus $2,198 million, a 3% increase, and the MD&A states that foreign exchange favorably affected year-over-year revenue growth by approximately 4%. Research and development expenses were $698 million in 2025, supporting more than 300 programs, with a significant share focused on product lifecycle innovation that broadens existing products into new species, formulations, and countries.

Hidden risk.The most easily missed item is the Fiscal Year Alignment. Effective January 1, 2026, Zoetis eliminated the one-month reporting lag for its international subsidiaries and moved their year-end to December 31. The filing says this pulled sales into the fourth quarter of 2025, adding an approximate 2.5% to 3.5% increase to International segment sales, a trend it does not expect to recur at the end of 2026. Some December 2025 customer orders were also delayed into the first quarter of 2026, so quarterly comparisons are distorted. Separately, long-term debt rose to $9.04 billion from $5.22 billion while equity fell to $3.33 billion from $4.77 billion.